TRDA Share Price Performance
US$7.72
0.75 (10.76%)
60.4% undervalued intrinsic discount
US$19.50
Fair Value
Price US$7.72
AnalystConsensusTarget US$19.50
AnalystHighTarget US$25.00
Fair ValueUS$19.50
Share Pricen/a
Entrada Therapeutics, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 7 Fair Values set on narratives written by author
TRDA Community Narratives
AN
Fair Value
·Fair Value US$19.5 60.4% undervalued intrinsic discount
Early Genetic Medicine Pipeline And Cash Runway Will Support Long Term Neuromuscular Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$25 69.1% undervalued intrinsic discount
DMD Franchise And Ocular Pipeline Will Create Multiple Long Term Genetic Medicine Opportunities
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Early Genetic Medicine Pipeline And Cash Runway Will Support Long Term Neuromuscular Opportunity
Entrada Therapeutics is aiming to bring genetic medicines to hard-to-treat muscle and eye diseases, with early signs of benefit in a small study and a platform designed to reach the cells that help muscles repair themselves. The upside hinges on whether bigger trials confirm these early results before cash needs force new fundraising, and whether rivals with broader or easier treatments crowd out its niche patient groups.Read more
AN
US$19.5
60.4% undervalued intrinsic discount
Fair Value
Profit Margin
19.04%
Future PE
76.57x
Price in 2029
US$24.2
DMD Franchise And Ocular Pipeline Will Create Multiple Long Term Genetic Medicine Opportunities
Entrada Therapeutics is trying to build a new kind of genetic medicine platform, starting with an early sign of improved movement in children with Duchenne muscular dystrophy and expanding into eye diseases and other muscle conditions through partnerships. The upside hinges on whether those early results hold up in larger studies and whether regulators accept the kind of evidence needed to bring the first treatment to patients sooner.Read more
AN
US$25
69.1% undervalued intrinsic discount
Fair Value
Profit Margin
18.66%
Future PE
31.63x
Price in 2029
US$30.99
Trending Discussion
Recently Updated Narratives
AN
Early Genetic Medicine Pipeline And Cash Runway Will Support Long Term Neuromuscular Opportunity
Fair Value: US$19.5 60.4% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DMD Franchise And Ocular Pipeline Will Create Multiple Long Term Genetic Medicine Opportunities
Fair Value: US$25 69.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Entrada Therapeutics, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -4.61
- -2,366.87%
- -2,895.05%
- 0%
About TRDA
- Founded
- 2016
- Employees
- 152
- CEO
- WebsiteView website
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
